American Association for Cancer Research
ccr-23-0956_supplementary_table_s6_suppts6.docx (63.76 kB)

Supplementary Table S6 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients

Download (63.76 kB)
journal contribution
posted on 2023-10-13, 07:40 authored by Javier Pascual, Miguel Gil-Gil, Paula Proszek, Christoph Zielinski, Alistair Reay, Manuel Ruiz-Borrego, Rosalind Cutts, Eva M. Ciruelos Gil, Andrew Feber, Montserrat Muñoz-Mateu, Claire Swift, Begoña Bermejo, Jesus Herranz, Mireia Margeli Vila, Antonio Antón, Zsuzsanna Kahan, Tibor Csöszi, Yuan Liu, Daniel Fernandez-Garcia, Isaac Garcia-Murillas, Michael Hubank, Nicholas C. Turner, Miguel Martín

Supplementary Table 6. Summary of all baseline mutations identified for the 146 patients with ctDNA detection.


Pfizer (Pfizer Inc.)

AstraZeneca (AstraZeneca PLC)

AMUMA (patient association donation)



Prognostic and predictive biomarkers to cyclin-dependent kinases 4 and 6 inhibitors are lacking. Circulating tumor DNA (ctDNA) can be used to profile these patients and dynamic changes in ctDNA could be an early predictor of treatment efficacy. Here, we conducted plasma ctDNA profiling in patients from the PEARL trial comparing palbociclib+fulvestrant versus capecitabine to investigate associations between baseline genomic landscape and on-treatment ctDNA dynamics with treatment efficacy. Correlative blood samples were collected at baseline [cycle 1-day 1 (C1D1)] and prior to treatment [cycle 1-day 15 (C1D15)]. Plasma ctDNA was sequenced with a custom error-corrected capture panel, with both univariate and multivariate Cox models used for treatment efficacy associations. A prespecified methodology measuring ctDNA changes in clonal mutations between C1D1 and C1D15 was used for the on-treatment ctDNA dynamic model. 201 patients were profiled at baseline, with ctDNA detection associated with worse progression-free survival (PFS)/overall survival (OS). Detectable TP53 mutation showed worse PFS and OS in both treatment arms, even after restricting population to baseline ctDNA detection. ESR1 mutations were associated with worse OS overall, which was lost when restricting population to baseline ctDNA detection. PIK3CA mutations confer worse OS only to patients on the palbociclib+fulvestrant treatment arm. ctDNA dynamics analysis (n = 120) showed higher ctDNA suppression in the capecitabine arm. Patients without ctDNA suppression showed worse PFS in both treatment arms. We show impaired survival irrespective of endocrine or chemotherapy-based treatments for patients with hormone receptor–positive/HER2-negative metastatic breast cancer harboring plasma TP53 mutations. Early ctDNA suppression may provide treatment efficacy predictions. Further validation to fully demonstrate clinical utility of ctDNA dynamics is warranted.

Usage metrics

    Clinical Cancer Research





    Ref. manager